bexagliflozin (Brenzavvy) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: OC[C@H]1O[C@@H](c2ccc(Cl)c(Cc3ccc(OCCOC4CC4)cc3)c2)[C@H](O)[C@@H](O)[C@@H]1O
  • InChIKey: BTCRKOKVYTVOLU-SJSRKZJXSA-N
  • Mol. Mass: 464.94
  • ALogP: 2.0
  • ChEMBL Molecule:
    bexagliflozin  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

bexagliflozin | egt0001442 | egt-0001442 | egt-1442 | thr-1442

Organizations (4)

Research & Development (4)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (1)


 

Diabetes Mellitus, Type 2 (approved 2023)

Experimental Indications - Clinical Trial Phases 1-4 (3)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Essential Hypertension (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial Organizations: 4

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue